Physician profile
David Castillo
NPI 1114286267
$3,467.70
in general payments reported to CMS, 2019-2025
30 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $453 · 2021: $290 · 2022: $1,083 · 2023: $633 · 2024: $225 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $831.57 | 2021-2024 | Rinvoq, Skyrizi |
| Amgen INC. | $474.35 | 2019-2024 | Repatha |
| Pfizer INC. | $348.56 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $282.97 | 2019-2025 | |
| Allergan, INC. | $244.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $214.86 | 2020-2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $171.44 | 2022-2025 | Camzyos |
| Cardiovascular Systems INC. | $126.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $102.82 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.28 | 2020-2025 | Lifevest |
| Sun Pharmaceutical Industries INC. | $91.01 | 2021-2022 | |
| Gilead Sciences, INC. | $81.97 | 2022-2023 | Veklury |
| Stryker Corporation | $40.24 | 2025 | Flowtriever |
| Alexion Pharmaceuticals, INC. | $31.77 | 2025 | Ultomiris |
| Cvrx, INC. | $31.74 | 2025 | Barostim Neo System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $28.54 | 2025 | Collagenase Santyl |
| Merck Sharp & Dohme LLC | $24.63 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Chiesi USA, INC. | $24.44 | 2019 | |
| Horizon Therapeutics Plc | $23.73 | 2023 | Uplizna |
| Vyne Pharmaceuticals INC. | $21.50 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $20.64 | 2023 | Valchlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.02 | 2019 | |
| Global Blood Therapeutics, INC. | $17.81 | 2021 | |
| Ucb, INC. | $16.91 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.71 | 2020 | |
| Csl Behring | $16.62 | 2021 | |
| Novo Nordisk INC | $14.95 | 2025 | |
| Portola Pharmaceuticals, LLC | $14.83 | 2019 | |
| Leo Pharma INC. | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.